NASDAQ:ADAG

Adagene Stock Insider Trading

Healthcare > Biotechnology

Buy ADAG

*Your capital is at risk

$3.46

+0.0700 (+2.06%)

At Close: Jun 03, 2026

Adagene Stock Insider Power

Based on the 73 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 4.95M and sold 0 ADAG shares in the last 73 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 73 transactions)	100.00
● Buy	4.95M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 18, 2026 Buy	Nonqualified Stock Option (Right to Buy)	Zhou Ling Ed Of Human Resources	Officer	20 000 Value: $20.8K
Mar 18, 2026 Buy	Incentive Stock Option (Right to Buy)	Do Cuong V Director	Director	40 000 Value: $32.0K
Mar 18, 2026 Buy	Incentive Stock Option (Right to Buy)	Zhao Qinghai Chief Manufacturing Officer	Officer	80 000 Value: $162.6K
Mar 18, 2026 Buy	Adagene Ordinary Shares	Chane-du Mickael Yannick Chief Strategy Officer	Officer	0 Value: $0
Mar 18, 2026 Buy	Adagene Ordinary Shares	Chane-du Mickael Yannick Chief Strategy Officer	Officer	0 Value: $0
Mar 18, 2026 Buy	Incentive Stock Option (Right to Buy)	Chane-du Mickael Yannick Chief Strategy Officer	Officer	400 000 Value: $550.4K
Mar 18, 2026 Buy	Incentive Stock Option (Right to Buy)	Chane-du Mickael Yannick Chief Strategy Officer	Officer	400 000 Value: $812.8K
Mar 18, 2026 Buy	Ordinary Shares	Tam Man Kin Chief Financial Officer	C-Suite Officer	0 Value: $0
Mar 18, 2026 Buy	Restricted Stock Unit	Tam Man Kin Chief Financial Officer	C-Suite Officer	0 Value: $0
Mar 18, 2026 Buy	Nonqualified Stock Option (Right to Buy)	Tam Man Kin Chief Financial Officer	C-Suite Officer	100 000 Value: $203.2K
Mar 18, 2026 Buy	Nonqualified Stock Option (Right to Buy)	Tam Man Kin Chief Financial Officer	C-Suite Officer	50 000 Value: $52.0K
Mar 18, 2026 Buy	Nonqualified Stock Option (Right to Buy)	Tam Man Kin Chief Financial Officer	C-Suite Officer	138 519 Value: $205.0K
Mar 18, 2026 Buy	Nonqualified Stock Option (Right to Buy)	Tam Man Kin Chief Financial Officer	C-Suite Officer	74 886 Value: $137.0K
Mar 18, 2026 Buy	Nonqualified Stock Option (Right to Buy)	Tam Man Kin Chief Financial Officer	C-Suite Officer	40 000 Value: $53.2K
Mar 18, 2026 Buy	Nonqualified Stock Option (Right to Buy)	Tam Man Kin Chief Financial Officer	C-Suite Officer	252 448 Value: $436.7K
Mar 18, 2026 Buy	Nonqualified Stock Option (Right to Buy)	Tam Man Kin Chief Financial Officer	C-Suite Officer	50 000 Value: $77.5K
Mar 18, 2026 Buy	Nonqualified Stock Option (Right to Buy)	Tam Man Kin Chief Financial Officer	C-Suite Officer	100 000 Value: $140.8K
Mar 18, 2026 Buy	Restricted Stock Unit	Luo Peter Chief Executive Officer	CEO / President	0 Value: $0
Mar 18, 2026 Buy	Ordinary Shares	Luo Peter Chief Executive Officer	CEO / President	0 Value: $0
Mar 18, 2026 Buy	Restricted Stock Unit	Luo Peter Chief Executive Officer	CEO / President	0 Value: $0
Mar 18, 2026 Buy	Ordinary Shares	Luo Peter Chief Executive Officer	CEO / President	0 Value: $0
Mar 18, 2026 Buy	Incentive Stock Option (Right to Buy)	Luo Peter Chief Executive Officer	CEO / President	2 250 Value: $12.6K
Mar 18, 2026 Buy	Incentive Stock Option (Right to Buy)	Luo Peter Chief Executive Officer	CEO / President	45 980 Value: $636.8K
Mar 18, 2026 Buy	Incentive Stock Option (Right to Buy)	Luo Peter Chief Executive Officer	CEO / President	500 000 Value: $520.0K
Mar 18, 2026 Buy	Incentive Stock Option (Right to Buy)	Luo Peter Chief Executive Officer	CEO / President	500 000 Value: $665.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ADAGENE INC.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical tr...

Read Full Profile Here